{"id":49432,"date":"2026-03-12T10:52:03","date_gmt":"2026-03-12T08:52:03","guid":{"rendered":"https:\/\/www.incliva.es\/incliva-avanza-hacia-la-medicina-de-precision-en-la-enfermedad-renal-a-traves-del-ensayo-europeo-ckd-biomatch\/"},"modified":"2026-03-12T11:35:20","modified_gmt":"2026-03-12T09:35:20","slug":"incliva-advances-towards-precision-medicine-in-kidney-disease-through-the-european-ckd-biomatch-trial","status":"publish","type":"post","link":"https:\/\/www.incliva.es\/en\/incliva-advances-towards-precision-medicine-in-kidney-disease-through-the-european-ckd-biomatch-trial\/","title":{"rendered":"INCLIVA advances towards precision medicine in kidney disease through the European CKD bioMatch trial"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><style type=\"text\/css\">@media only screen and (max-width:1532px) {.fusion-title.fusion-title-1{margin-top:10px!important;margin-bottom:15px!important;}}@media only screen and (max-width:640px) {.fusion-title.fusion-title-1{margin-top:10px!important;margin-bottom:10px!important;}}<\/style><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"margin-top:10px;margin-bottom:15px;\"><h4 class=\"title-heading-left\" style=\"margin:0;\"><ul>\n<li>The aim is to incorporate biomarkers that help identify patients at higher risk of progression and guide therapeutic strategies<\/li>\n<li>Today, the second Thursday in March, is World Kidney Day, a day to reflect on the challenges in nephrology given the wide variability in patient response to treatments<\/li>\n<\/ul><\/h4><\/div><div ><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none\" style=\"margin-bottom:20px;\"><img width=\"1920\" height=\"1080\" title=\"web Grupo Invest\" src=\"https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/web-Grupo-Invest.jpg\" class=\"img-responsive wp-image-49438\" srcset=\"https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/web-Grupo-Invest-200x113.jpg 200w, https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/web-Grupo-Invest-400x225.jpg 400w, https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/web-Grupo-Invest-600x338.jpg 600w, https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/web-Grupo-Invest-800x450.jpg 800w, https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/web-Grupo-Invest-1200x675.jpg 1200w, https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/web-Grupo-Invest.jpg 1920w\" sizes=\"(max-width: 640px) 100vw, 1200px\" \/><\/span><\/div><div class=\"fusion-text fusion-text-1\" style=\"transform:translate3d(0,0,0);\"><p>Researchers from the INCLIVA Biomedical Research Institute at the University Clinical Hospital of Valencia are contributing, through their participation in the European CKD bioMatch trial, to the advancement of precision medicine in chronic kidney disease, aimed at personalising patient treatment through biomarker-guided therapies.<\/p>\n<p>Chronic kidney disease affects hundreds of millions of people worldwide and remains a major cause of morbidity, mortality and healthcare burden. Although important therapeutic advances have emerged in recent years, one of the central challenges in nephrology is the variability in how patients respond to treatment. A therapy that is highly effective for one patient may provide limited benefit for another. Addressing this variability is one of the key goals of precision medicine.<\/p>\n<p>In 2023, the European <a href=\"https:\/\/www.prime-ckd.com\/\">PRIME-CKD<\/a> project was launched, with INCLIVA participating, with the aim of addressing this challenge through the integration of clinical research, biomarker discovery and implementation science. One of the main studies within this initiative is the CKD bioMatch trial, a multinational clinical study designed to investigate whether biological markers can help guide treatment decisions in patients with progressive chronic kidney disease.<\/p>\n<p>The CKD bioMatch trial is being conducted in several European countries including Denmark, Germany, Spain, the United Kingdom and Sweden. The study plans to recruit patients with progressive CKD who will be followed for three years. By combining biomarker information with clinical data, investigators aim to identify which patients are most likely to benefit from specific therapeutic strategies. At\u00a0INCLIVA, patient recruitment at the Hospital Cl\u00ednico Universitario de Valencia is progressing rapidly.<\/p>\n<p><em>\u201cOur goal is to move toward a model of care in which treatment decisions in chronic kidney disease are informed not only by traditional clinical parameters but also by validated biological signals. Biomarkers may help us identify patients at higher risk of progression and guide more personalised therapeutic strategies\u201d, <\/em>highlights <strong>Dr Jos\u00e9 Luis G\u00f3rriz,<\/strong> principal investigator of PRIME-CKD at INCLIVA, where he coordinates the <a href=\"https:\/\/incliva.portalinvestigacion.com\/grupos\/406\">Renal Disease Group<\/a>.<\/p>\n<p>In recent years, several innovative therapies have demonstrated the ability to slow the progression of chronic kidney disease and reduce cardiovascular risk. However, treatment responses vary considerably between individuals. Dr <strong>Francesc Moncho<\/strong>, clinician scientist at INCLIVA Valencia, highlights the clinical relevance of the study.<\/p>\n<p>\u201cNew therapies have transformed the treatment landscape of chronic kidney disease. However, not all patients respond equally. Through studies such as CKD bioMatch, we hope to better understand these differences and optimise treatment decisions so that each patient receives the therapy most likely to benefit them.\u201d<\/p>\n<p>Professor <strong>Hiddo L Heerspink<\/strong>, coordinator of the PRIME-CKD project at the University Medical Center Groningen in the Netherlands, notes that the study represents an important step toward personalised kidney care. \u201cBy using biological markers to guide therapy, we aim to ensure that the right treatment reaches the right patient at the right time.\u201d<\/p>\n<p>Ultimately, PRIME-CKD seeks to move nephrology toward a future in which biomarker guided strategies help personalise treatment, improve outcomes and slow the progression of kidney disease across Europe.<\/p>\n<p>This project has received funding from the European Union\u2019s research and innovation programme under the Horizon Europe call HORIZON HLTH 2022 TOOL 11 01 as part of the PRIME-CKD consortium.<\/p>\n<\/div><div ><span class=\" fusion-imageframe imageframe-none imageframe-2 hover-type-none\" style=\"margin-bottom:20px;\"><img width=\"529\" height=\"51\" title=\"Imagen1\" src=\"https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/Imagen1-2.jpg\" class=\"img-responsive wp-image-49433\" srcset=\"https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/Imagen1-2-200x19.jpg 200w, https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/Imagen1-2-400x39.jpg 400w, https:\/\/www.incliva.es\/wp-content\/uploads\/2026\/03\/Imagen1-2.jpg 529w\" sizes=\"(max-width: 640px) 100vw, 529px\" \/><\/span><\/div><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-0{width:100% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-0{width:100% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 0px;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":49438,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[189],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/posts\/49432"}],"collection":[{"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/comments?post=49432"}],"version-history":[{"count":9,"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/posts\/49432\/revisions"}],"predecessor-version":[{"id":49457,"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/posts\/49432\/revisions\/49457"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/media\/49438"}],"wp:attachment":[{"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/media?parent=49432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/categories?post=49432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.incliva.es\/en\/wp-json\/wp\/v2\/tags?post=49432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}